Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000819 · ClinicalTrials.gov registry record · Phase 2
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)
A Phase 2 study of HIV Infections and AIDS-Associated Nephropathy, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 8
- Study locations
NCT00000819: Completed Phase 2 study of HIV Infections and AIDS-Associated Nephropathy, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000819 is a Phase 2 study of HIV Infections and AIDS-Associated Nephropathy that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 54 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (88% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000819, a Phase 2 study of HIV Infections and AIDS-Associated Nephropathy, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 8
- Study locations
Study Summary
To determine the efficacy and safety of prednisone in patients with HIV-associated nephropathy. To determine the effects of prednisone on serum creatinine, urinary protein, and creatinine clearance. HIV-associated nephropathy is characterized by heavy proteinuria, rapidly progressive renal insufficiency, and distinct nephropathologic changes. The syndrome most often occurs in patients with advanced HIV disease. Little is known about the effects of corticosteroids on the progression of HIV disease. In light of the possible beneficial effects of corticosteroids on HIV-associated nephropathy, a controlled trial using prednisone is warranted.
Conditions Studied
Interventions
- DRUG Prednisone
Study Locations (8)
California
- UCLA CARE Center CRS - Los Angeles
- Ucsf Aids Crs - San Francisco
- Harbor-UCLA Med. Ctr. CRS - Torrance
Ohio
- Case CRS - Cleveland
- MetroHealth CRS - Cleveland
Indiana
- Indiana Univ. School of Medicine, Infectious Disease Research Clinic - Indianapolis
Maryland
- Johns Hopkins Adult AIDS CRS - Baltimore
New York
- Beth Israel Med. Ctr. (Mt. Sinai) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Est. Completion | 1996-09 |
| Phase | Phase 2 |
What the finished NCT00000819 record still lists
NCT00000819 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Prednisone is the first listed.
NCT00000819 lists 8 locations in 5 states (California, Ohio, Indiana).
Frequently Asked Questions
What is clinical trial NCT00000819 about?
NCT00000819 is a clinical study titled "A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)". To determine the efficacy and safety of prednisone in patients with HIV-associated nephropathy. To determine the effects of prednisone on serum creatinine, urinary protein, and creatinine clearance. HIV-associated nephropathy is characterized by heavy proteinuria, rapidly progressive renal insuffic...
What is the current status of trial NCT00000819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. Estimated completion is 1996-09.
What conditions does trial NCT00000819 study?
This clinical trial studies the following conditions: HIV Infections, AIDS-Associated Nephropathy.
What interventions are being tested in trial NCT00000819?
The interventions under investigation include: Prednisone (DRUG).
Who is sponsoring clinical trial NCT00000819?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000819 being conducted?
This trial has 8 study locations across California, Indiana, Maryland, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000819's enrollment target sits among peer trials
54 345th of 542 higher than 195 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy